skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: I haven't seen a question about Biosyent in a couple of months, it's trading near its 52 week low. You indicated in May the fundamentals looked good, the price is still is dropping possibly due to the sector. I am considering taking a position at this time, please advise your thoughts.
Thanks
Jim
Read Answer Asked by Jim on July 31, 2015
Q: Considering all the death crosses in their chart, it looks like Biosyent is in a condition where the technical indicators will rule the fundamentals for a bit. I bought it at the top end in an RRSP and TFSA (3%)so is it worth holding. Was the stock just stretched out too far in Q1 or are there some fundamental concerns? I don't have any issue holding on for a couple of quarters or buying a bit more when it bottoms if there are no serious fundamental concerns.
Read Answer Asked by Clarence on May 24, 2015
Q: Hello,

Since Jason Donville recommended Biosyent (RX) on December 24 I was in on what I perceived was a dip and luckily out again before it dipped another big chunk. Similar thing with Knight (GUD).

My question is whether there is a price point at which either of these become "no brainer" buys? For an investor willing to absorb some risk are we near that point with each stock at $7?
Read Answer Asked by Tim on May 21, 2015
Q: After being a top pick of Jason Donville on Dec 24/14,RX's price increased to $12.08 on Dec 31,but it had steadily & sharply declined to $7.57 on May 14 despite 2 good quarterly reports @ end of Feb & May 13.I am really confused.I bought a small amount @ $10. Please advise if this is a Hold,Sell or average down,Thanks for your normal great opinions & services
Read Answer Asked by Peter on May 19, 2015
Q: Guys,

Great service, I've only been a subscriber for a few days but have got more out of this then any other newsletter/board I've ever found. My question is on Biosyent- within the past week a second analyst has began covering the stock and has in my opinion very low EPS/Revenue estimates for 2016. Do you know who recently picked up coverage and what reasons they gave for estimates significantly below Cantor's? Thank you!
Read Answer Asked by Chad on April 21, 2015
Q: Yesterday, a member asked if we could see any news about RX.V. The company "advises that it is not aware of any material undisclosed business development that should account for the decrease in its stock price". Source: http://www.stockhouse.com/news/press-releases/2015/04/10/biosyent-comments-on-recent-market-activity. The stock is now up 9%.
Read Answer Asked by Matt on April 10, 2015
Q: Hi, I've been watching RX since it was about 11 dollars, hoping for an opportunity to get in. It has recently taken quite a dive to 8 dollars and looks like it might go down further. Has something changed with the company or would this be a good time to buy?

SYZ is doing the same thing. Is this a good time to get in or will it drop further?

Thanks!
Read Answer Asked by Carla on April 06, 2015
Q: Any reason to be concerned with this stock? Pulling back quite a bit in the past week. Would you be a buyer, seller or would you hold given the current price, market conditions and momentum of this stock? Do you have a price target or idea of what the 1 year consensus is?
Read Answer Asked by Tim on April 05, 2015
Q: Hi Peter,

I have a small position in Biosyent. Admittedly it had a very good run in 2014, but has gone a bit silent in recent months despite strong numbers. Would you see this as normal consolidation or are there other issues at play. I'm a bit underwater and would appreciate your thoughts on whether to hold or to move on.

Thanks
Read Answer Asked by Greg on March 19, 2015
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!